ICU Medical, Inc.
120.11-2.80 (-2.28%)
Oct 28, 4:00:00 PM EDT · NasdaqGS · ICUI · USD
Key Stats
Market Cap
2.97BP/E (TTM)
-Basic EPS (TTM)
-1.52Dividend Yield
0%Recent Filings
8-K
Q2 revenue dips, profits rise
ICU Medical reported Q2 2025 revenue of $548.9 million, down from $596.5 million last year, driven by a $63 million drop in Vital Care amid lower contract manufacturing. Yet gross margins climbed to 38% from 35%, fueling GAAP net income of $35.3 million versus a prior loss. A $41.8 million gain from business sale boosted results. Updated 2025 guidance narrows adjusted EBITDA to $380-390 million, but risks linger from the IV Solutions joint venture.
10-Q
Q2 FY2025 results
ICU Medical's Q2 FY2025 revenue dipped 7.9% y/y to $548.9M, driven by the May 1 divestiture of a 60% stake in its IV Solutions business for $209.5M cash, yet core consumables and infusion systems grew 4.3% and 2.4% y/y, respectively, lifting gross margins to 37.9% from 34.8% on synergies and efficiencies. Operating income rose to $10.6M from $7.7M, with diluted EPS at $1.43 versus a $0.88 loss, reconciled to 24.7M shares; the $41.8M gain on sale boosted net income to $35.3M. Cash stood at $300.0M after $247.8M debt paydown, yielding $62.5M operating cash flow and $28.2M free cash flow (derived). The joint venture contributed $2.8M equity earnings. Ongoing FDA scrutiny at Smiths Medical facilities poses regulatory risks.
8-K
Stockholders approve plan amendment
ICU Medical's stockholders approved the third amendment to its 2011 Stock Incentive Plan at the May 13, 2025 annual meeting, boosting available shares for awards and ISOs by 2,150,000 each to a total of 8,515,510. This expands equity incentive capacity while imposing a one-year minimum vesting for new grants, barring exceptions. Directors were unanimously elected. Stockholders also ratified Deloitte as auditors and endorsed executive pay.
10-Q
Q1 FY2025 results
ICU Medical posted solid Q1 FY2025 results, with revenues climbing 6.7% year-over-year to $604.7M, fueled by gains across consumables (up 9.1% to $266.2M), infusion systems (up 5.7% to $166.3M), and vital care (up 4.2% to $172.2M); gross margins expanded to 34.8% from 32.7%, thanks to price hikes and integration synergies. Operating income flipped positive at $12.9M, a stark turnaround from last year's $10.7M loss, though net loss narrowed to $15.5M or $(0.63) per diluted share from $39.5M or $(1.63), with the gap to operating mainly from $22.0M net interest expense. Cash from operations hit $51.3M, yielding free cash flow of $36.7M after $14.6M capex, while total debt eased to $1.5B with $289.7M in cash; post-quarter, the firm closed its IV solutions JV sale for $209.5M cash, earmarked for debt reduction. R&D ticked up 6.9% to $23.3M on project staffing. Yet regulatory hurdles linger, like the FDA's 2025 warning letter on pump modifications demanding new clearances.
8-K
Q1 revenue up 7%, loss narrows
ICU Medical reported Q1 2025 revenue of $604.7 million, up 7% from $566.7 million last year, driven by gains in consumables, infusion systems, and vital care. Gross margin improved to 35% from 33%, yet GAAP net loss narrowed to $15.5 million from $39.5 million, while adjusted EPS climbed to $1.72 from $0.96. Results met expectations amid integration costs. Risks persist from quality remediation and the IV Solutions joint venture.
IPO
Website
Employees
Sector
Industry
ATRC
AtriCure, Inc.
36.45-0.02
BAX
Baxter International Inc.
22.86-0.31
BDX
Becton, Dickinson and Company
184.21-2.83
INFU
InfuSystems Holdings, Inc.
10.45+0.44
ISRG
Intuitive Surgical, Inc.
545.39-5.86
MHUA
Meihua International Medical Te
0.26+0.01
MMSI
Merit Medical Systems, Inc.
82.79+0.04
NUWE
Nuwellis, Inc.
3.10-0.13
TFX
Teleflex Incorporated
130.58-1.97
UTMD
Utah Medical Products, Inc.
58.53-0.70